CoChat
Sign Up
Cited by 410Gastrointestinal motility and disordersEnhanced Recovery After SurgeryPelvic floor disorders treatments

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

Open access
Prather, Charlene M., Camilleri, Michael, Zinsmeister, Alan R., McKinzie, Sanna, Thomforde, George·2000·Gastroenterology
DOI 10.1016/s0016-5085(00)70251-4
Open this paper in CoChat — free accountOpen PDF

Abstract

Background & aims This study evaluated the effects of a partial 5-hydroxytryptamine (5-HT)(4) agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS).Methods After a 1 week run-in period, 24 patients with constipation-predominant IBS were randomized to 1 week of tegaserod, 2 mg twice daily, or placebo treatment. Scintigraphic gastric emptying, small bowel transit, and colonic transit were determined before administration of study drug and after 1 week on the medication. Colonic transit was also measured using radiopaque markers and a single radiograph on day 5.Results Gastric emptying was unaltered by tegaserod. Proximal colonic filling at 6 hours, a measure of orocecal transit, was accelerated by tegaserod (70.4% +/- 1.3% [mean +/- SEM] vs. placebo, 46.4 +/- 1.9; P = 0.015). Proximal colonic emptying half-time and geometric center at 48 hours were also accelerated by tegaserod compared with baseline, but not compared with placebo. Mean colonic transit time was similar in both groups at baseline and after drug administration (tegaserod, 59.5 +/- 2.1 hours; placebo, 62.1 +/- 2.1 hours).Conclusions Tegaserod accelerates orocecal transit, tends to accelerate colonic transit, and deserves further study in patients with constipation-predominant IBS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0016-5085(00)70251-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 3

  1. Pfannkuche, 1995, The properties of a new prokinetically active drug, SDZ HTF 919, Neurogastroenterol Motil, 7, 280
  2. Langaker, 1998, The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome, Digestion, 59, 20
  3. Thompson, 1992, Functional bowel disease and functional abdominal pain, Gastroenterol Int, 5, 75

Cited by

Sorted by citations

Items 201–300 of 410

Related

See all

Metadata

Authors
Prather, C. M., Camilleri, M., Zinsmeister, A. R., McKinzie, S., & Thomforde, G.
Affiliations
Mayo Clinic (US)
ORCID
Camilleri, Michael
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2000-03
Volume
118
Issue
3
Pages
463-468
ISSN
0016-5085 (ISSN-L)
DOI
10.1016/s0016-5085(00)70251-4
OpenAlex
W2095055104
Cited by
410
References
22
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 4 · 2016: 8 · 2015: 7 · 2014: 4 · 2013: 6 · 2012: 12
FWCI
36.61
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24DK02638-01, K24DK002638, R01-DK546881)
  • National Center for Research Resources (RR-00585, M01RR000585)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
Keywords
tegaserod, irritable bowel syndrome with constipation, orocecal transit, colonic transit, gastric emptying, small intestinal transit, 5-HT4 receptor agonist, scintigraphy, radiopaque markers
MeSH terms
Adult, Aged, Colon, Colonic Diseases, Functional, Constipation, Double-Blind Method, Gastrointestinal Transit, Guanidines, Humans, Indoles, Intestine, Small, Middle Aged, Radionuclide Imaging, Stomach, Time Factors, Serotonin Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review